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Abstract
 
Secreted protein, acidic and rich in cysteine (SPARC), also known as osteonectin or BM-40, is
a Ca
 
2
 
 
 
-binding matricellular glycoprotein involved in development, wound healing, and neo-
plasia. However, the role of SPARC in tumors is ill defined mostly because it is expressed by
both tumor and stromal cells, especially inflammatory cells. We analyzed the respective roles of
host- and tumor-derived SPARC in wild-type and congenic SPARC knockout (SPARC
 
 
 
/
 
 
 
)
mice on a BALB/c genetic background injected into the mammary fat pad with SPARC-
producing mammary carcinoma cells derived from c-erB2 transgenic BALB/c mice. Reduced
tumor growth but massive parenchyma infiltration, with large areas of necrosis and impaired
vascularization were observed in SPARC
 
 
 
/
 
 
 
 mice. Immunohistochemical analysis showed a
defect in collagen type IV deposition in the stroma of lobular tumors from SPARC
 
 
 
/
 
 
 
 mice.
Chimeric mice expressing SPARC only in bone marrow–derived cells were able to organize
peritumoral and perilobular stroma, whereas reciprocal chimeras transplanted with bone marrow
from SPARC
 
 
 
/
 
 
 
 mice developed tumors with less defined lobular structures, lacking assembled
collagen type IV and with a parenchyma heavily infiltrated by leukocytes. Together, the data
indicate that SPARC produced by host leukocytes, rather than the tumor, determines the assembly
and function of tumor-associated stroma through the organization of collagen type IV.
Key words: osteonectin • extracellular matrix • leukocyte inﬁltration • tumor–host interactions
 
Introduction
 
Interactions between tumor and inflammatory cells represent
a key issue in the complexity of neoplastic transformation
and tumor progression (1, 2). Such interactions determine
either tumor progression or regression through several
mechanisms, including stroma formation, angiogenesis, adhe-
sion and cell migration to and from the tumor, and cytokine
and chemokine milieu, plus other factors that contribute to
tissue remodeling. Emerging evidence points to host leuko-
cytes rather than tumor cells as the source of such determining
factors. This may be due simply to the availability of new tools
to study leukocyte function, including mice deleted for genes
encoding leukocyte-produced factors. Indeed, KO mice
provide a direct means to examine the in vivo molecular
events responsible for neoplastic transformation. The impor-
tance of inflammatory cytokines in determining the tumor
microenvironment has been underlined by the findings that
TNF
 
 
 
 KO mice are resistant to skin carcinogenesis (3),
whereas those lacking IL-1
 
 
 
 are resistant to the development
of experimental metastases (4). Furthermore, 
 
op
 
/
 
op
 
 mice,
which are naturally deficient in CSF-1 (5, 6), show impaired
tumor growth (7) and progression (8). Matrix metalloprotein-
ase (MMP)-9 has been shown to be required for progression
of skin carcinogenesis, and bone marrow transplantation
(BMT) experiments have demonstrated that leukocytes are
the critical source of MMP-9 in the tumor environment
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Abbreviations used in this paper:
 
 BMT, bone marrow transplantation; ECM,
extracellular matrix; MMP, matrix metalloproteinase; PECAM-1, platelet–
endothelial cell adhesion molecule 1; SPARC, secreted protein, acidic
and rich in cysteine.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
Tumor Leukocyte and Vessel Infiltration in Absence of Host-produced SPARC
 
1476
(9). MMP-9 produced by host macrophages has also been
shown to promote outgrowth of human ovarian carcinoma
xenotransplanted into 
 
nu/nu
 
 mice (10).
In this work, we used a KO mouse model to analyze the
role of a potentially regulatory matricellular protein in tu-
mor–host interactions. Secreted protein, acidic and rich in
cysteine (SPARC), also known as osteonectin or BM-40, is
a Ca
 
2
 
 
 
-binding matricellular glycoprotein that binds to a
range of extracellular matrix (ECM) components such as
thrombospondin-I (11), vitronectin (12), fibrillar collagen
(types I, II, III, and V), and collagen type IV (13, 14), the
predominant structural component of the basement mem-
brane. SPARC is expressed during development and, in
adults, during processes requiring ECM turnover such as
wound healing and tumor progression. The amino acid se-
quence of SPARC is highly conserved among species from
 
Drosophila melanogaster
 
 (15) to humans (16). A variety of in
vitro papers have suggested a role for SPARC in the regu-
lation of cell adhesion and proliferation, and in the modu-
lation of cytokine activity (17–20). Although SPARC
expression appears to be deregulated in transformed cells
(21–23), its inhibition by antisense RNA diminished both
the adhesive and invasive capacities of human melanoma
cells in vitro and in xenotransplanted 
 
nu/nu
 
 mice (24). The
role of SPARC in neoplastic cell transformation, condi-
tioning inflammation, and leukocyte trafficking has not
been well defined in vivo, where the major phenotypes re-
ported so far in SPARC KO mice are cataract formation
(25–27) and osteopenia (28, 29). The former is associated
with an altered collagen type IV protein (30).
To obtain SPARC
 
 
 
/
 
 
 
 mice on a genetic background
suitable for tissue transplantation and immunological stud-
ies, we backcrossed SPARC KO mice (26) that were origi-
nally on a mixed 129 background to BALB/c mice, fol-
lowed by interbreeding to obtain a congenic BALB/c/
SPARC
 
 
 
/
 
 
 
 strain that retains the original phenotype de-
scribed in 129 mice (unpublished data). We also back-
crossed outbred mice transgenically expressing the rat
oncogene c-erB2 (HER-2/neu) driven by the mouse mam-
mary tumor virus promoter to BALB/c mice. Female mice
carrying the activated rat HER-2/neu oncogene present
high numbers of breast tumor nodules characterized as lob-
ular carcinomas with lobes defined by connective septa
containing collagen type IV (31). The onset of mammary
gland hyperplasia and carcinoma have been carefully char-
acterized in these transgenic mice (32), which were used as
the source of mammary carcinomas and cell lines in the
present work.
We evaluated the role of tumor-derived SPARC in
stroma formation and tumor outgrowth in wild-type and
congenic SPARC
 
 
 
/
 
 
 
 mice injected with SPARC-produc-
ing mammary carcinoma cells. We also analyzed the role of
leukocyte-produced SPARC, using chimeric mice express-
ing SPARC only in donor BM-derived cells. Our results
revealed impairment of growth, vascularization, and stroma
formation in tumors implanted into SPARC
 
 
 
/
 
 
 
 mice. Re-
duced lobular structure and intervening stroma in the ab-
 
sence of host-produced SPARC were associated with re-
duced collagen type IV deposition, an event that might
favor leukocyte infiltration of tumor parenchyma. This
phenotype was reversed by transplanting BM from SPARC
 
 
 
/
 
 
 
donors. Thus, the organization of tumor stroma depends
on SPARC produced by host leukocytes rather than on tu-
mor-derived SPARC.
 
Materials and Methods
 
Mice and Tumors.
 
SPARC KO mice on a mixed 129SV/
C57BL/6 background (26) were provided by C. Howe (The
Wistar Institute, Philadelphia, PA). Mice were backcrossed for 12
generations with BALB/cAnNCrl (Charles River Laboratories)
to obtain congenic SPARC
 
 
 
/
 
 
 
 mice. Heterozygous and ho-
mozygous animals were identified by Southern blot analysis using
the 280-bp HindIII-BamHI fragment of SPARC cDNA as a
probe. Mouse tail DNA was digested with restriction enzyme
NSII to distinguish the wild-type gene (5.3-kb fragment) from
the KO gene (7.9-kb fragment).
Female BALB-neuT mice are transgenic for the activated form
of the rat c-erB2 oncogene and develop mammary tumors in-
volving all mammary glands (32). Mice were bred and maintained
at the Istituto Nazionale Tumori under standard conditions ac-
cording to institutional guidelines.
N1G, N2C (thoracic), and N3D (inguinal) primary mammary
carcinoma cell lines were derived from female BALB-neuT mice.
Tumors were removed and, in a sterile environment, cleaned of
fat, large vessels, and necrotic areas, minced with scissors, and
placed in warm trypsin (37
 
 
 
C for 30 min). After washing with
DMEM (Bio Whittaker) and the addition of 10% heat-inacti-
vated FCS (Bio Whittaker), tissue was passed through strainers
and washed again. Cells were counted and seeded in 6-well plates
at 0.4 
 
 
 
 10
 
6
 
 cells/ml in DMEM plus 20% FCS. Tumorigenicity
of carcinoma cells was assayed in wild-type, SPARC
 
 
 
/
 
 
 
, and chi-
meric mice injected s.c. into the mammary fat of the inguinal re-
gion with the cells at a predetermined minimal lethal dose. Tu-
mor take and volume were monitored twice per week. Tumors
were measured with calipers in the two perpendicular diameters,
and tumor volume (mm
 
3
 
) was calculated as long diameter 
 
 
 
 short
diameter
 
2
 
.
 
Morphological Analysis and Immunohistochemistry.
 
For histologi-
cal evaluation, tumor fragments were fixed in 10% neutral-buff-
ered formalin, embedded in paraffin, sectioned (5 
 
 
 
m), and
stained with hematoxylin and eosin (H&E) or Masson’s trichrome.
H&E-stained sections showed that the transplanted tumors are
similar to the primary neoplasia (31). Cancer cells grew in solid
nests forming lobules and less frequently ductular structures en-
dowed with dense, well-vascularized, connective tissue.
For immunohistology, tumor fragments were embedded in
OCT compound, snap frozen, and stored at 
 
 
 
80
 
 
 
C. For immu-
nohistochemical analysis, 5-
 
 
 
m cryostat sections were fixed in ac-
etone and incubated for 1 h with the following: (a) mouse anti-
osteonectin mAb (clone ON1–1; Takara Biomedicals); (b) rabbit
polyclonal Ab against mouse collagen type IV (AB756; Chemi-
con); (c) rabbit anti–mouse collagen type I (Biodesign Interna-
tional); (d) rat anti–mouse mAb CD31 (platelet–endothelial cell
adhesion molecule 1 [PECAM-1]); (e) biotinylated rat mAb
against mouse CD45 (clone 30-F11) and Ly-6G (clone RB6–
8C5); (f) fluorescein-isothiocyanate (FITC)-conjugated mAbs
against CD11c (clone HL3), CD11b (clone MI/70), CD4 (clone
GK 1.5; all from BD Biosciences); and (g) F4/80 (clone CI: A3–1;T
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Caltag). After washing, sections were sequentially overlaid with
biotinylated goat anti–rabbit IgG for 30 min and with avidin–per-
oxidase complex for 30 min (Sigma-Aldrich). Avidin–peroxidase
complex or peroxidase-conjugated rabbit anti-FITC antibody
(DakoCytomation) was used as secondary antibody for sections in-
cubated with biotinylated primary antibodies or FITC-conjugated
primary antibody, respectively. Antigen was revealed with 3,3
 
 
 
-
diaminobenzidine (Sigma-Aldrich) according to the manufacturer’s
instructions. Sections were counterstained with Mayer’s hematox-
ylin, dehydrated in graded alcohol (70, 95, and 100% ethanol), and
mounted in BDH mounting medium (Merck Eurolabs). All im-
munolocalization experiments were repeated three times with
multiple sections, including negative controls for determination of
background staining. All images were digitally captured on a mi-
croscope (Nikon) equipped with a digital camera (DXM1200; Ni-
kon) and analyzed using ACT1 software. The number of mi-
crovessels and immunostained cells was determined by light
microscopy at 400 magnification in 10 fields on a 1-mm
 
2
 
 grid and
is given as cells/mm
 
2
 
 (mean 
 
 
 
 SD).
 
In Situ Hybridization.
 
The presence of cytokine mRNA was
investigated by in situ hybridization using TNF
 
 
 
 and IFN
 
 
 
cDNA probes (33). Each specific probe (1 
 
 
 
g) was labeled with
biotin using the Renaissance Random Primer Labeling Kit (NEN
Life Science Products).
Cryostat sections were processed for in situ hybridization as
described previously (33) except for probe detection. In brief,
slides were air dried, rehydrated in PBS, blocked with 10% FCS
in PBS, incubated with avidin–peroxidase complex for 30 min,
and washed. Reactivity was revealed with 3,3
 
 
 
-diaminobenzidine
followed by Mayer’s hematoxylin counterstaining. Pst-1–digested
pUC9 plasmid fragments were used in negative control sections.
 
Treatment of SPARC
 
 
 
/
 
 
 
 and Congenic SPARC
 
 
 
/
 
 
 
 Mice with
Anti-TNF
 
 
 
 and -INF
 
 
 
 Neutralizing mAbs.
 
SPARC
 
 
 
/
 
 
 
 and
SPARC
 
 
 
/
 
 
 
 mice were injected s.c. with N2C mammary carci-
noma cells at the minimal lethal dose and treated with 200 
 
 
 
g of
anti-TNF
 
 
 
 (V1Q hybridoma, provided by D. Mannell, Univer-
sity of Regensburg, Regensburg, Germany) and 200 
 
 
 
g of anti-
 
IFN
 
 
 
 (AN18 hybridoma, provided by G. Garotta, Roche, Basel,
Switzerland) mAb twice weekly starting on day 1 after tumor in-
jection. Tumor take and volume were monitored twice per week.
 
BMT.
 
SPARC
 
 
 
/
 
 
 
 and SPARC
 
 
 
/
 
 
 
 mice on a BALB/c back-
ground were lethally 
 
 
 
 irradiated with 900 cGy (given as a split
dose 450 
 
  
 
450 cGy with a 3-h interval between the first and the
second irradiation), whereas CB6F1 (SPARC
 
 
 
/
 
 
 
) mice received
a total of 950 cGy (500 
 
  
 
450). 2 h later, mice were injected i.v.
with 2 
 
 
 
 10
 
7
 
-nucleated cells obtained from SPARC
 
 
 
/
 
 
 
 or
SPARC
 
 
 
/
 
 
 
 donors as follows. BM-derived cells were obtained
by flushing the cavity of freshly dissected femurs with saline.
Flushed cells were dispersed by pipetting across strainers, washed,
and resuspended in saline. Recipient mice received 0.4 mg/ml
gentalyn added to the drinking water starting 1 wk before irradia-
tion and maintained thereafter. To verify engraftment, PBMCs
withdrawn from the retro-orbital sinus at 4, 6, and 8 wk after
BMT were stained with FITC-conjugated mouse anti–mouse
H-2K
 
b
 
 and PE-conjugated mouse anti–mouse H-2K
 
d
 
, as well as
isotype control FITC- and PE-conjugated mouse IgG2a, and
analyzed by cytofluorimetry. A total of 5,000-gated events were
collected on a FACScan™ (Becton Dickinson) and analyzed using
CELLQuest™ software (Becton Dickinson). At 8 wk after BMT,
chimeric mice were injected s.c. with 5 
 
 
 
 10
 
5
 
 N2C tumor cells.
 
RNA and Northern Blot Analysis.
 
Total RNA was extracted
from N1G, N2C, and N3D cells using TRIzol (Promega) and al-
iquots (10 
 
 
 
g) were run on a 1.0% agarose-formaldehyde gel,
Figure 1. SPARC expression in primary mammary carcinoma cell
lines. Northern blotting (A) and immunohistochemical (B) analysis of
N2C (a), N1G (b), and N3D (c) cell lines. Northern blot analysis was
performed by sequential hybridization with SPARC and  -actin probes.
SPARC staining localized in the cytoplasm of all three cell lines, but the
higher amount of SPARC produced by N2C appeared to show an apparent
staining of the nuclei, which are normally negative.
Figure 2. Histological features and SPARC expression of N2C tu-
mors in SPARC /  and SPARC /  mice. (A) N2C tumors grew in
SPARC /  mice as solid nests forming lobules (LB) embedded in dense,
well-vascularized, connective tissue (arrowheads) and surrounded by a well-
defined connective capsule (CA). Tumors from SPARC /  mice were
smaller and histologically characterized by less defined lobules, not completely
surrounded by the stromal septa (arrowheads) and frequently presenting
necrotic (n) areas. Original magnification, 40. (B) N2C tumor cells grown in
SPARC /  or SPARC /  mice produced SPARC as detected immuno-
histochemically with anti-SPARC mAbs. In the SPARC /  host, all of the
cells (tumor [Tu] and stromal [S]) were strongly reactive. In the SPARC / 
host, only the tumor cells (Tu) were positive for SPARC expression, whereas
the massive leukocyte infiltrate (L) invading one septum, as well as stromal
cells (S) in the thin connective septa, were completely negative. Formalin
fixed, paraffin embedded sections are shown. Original magnification, 200.T
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N2C cells expressing the highest level of tumor-derived
SPARC (Fig. 1) were selected for injection into SPARC
 
 
 
/
 
 
 
and SPARC
 
 
 
/
 
 
 
 mice. Compared with tumors from wild-
type mice, those from SPARC
 
 
 
/
 
 
 
 mice were smaller and
histologically characterized by undefined lobules, frequently
presenting necrotic central areas (Fig. 2 A). The lobules
were not completely delineated by the stromal septa, which
appeared generally thin (Fig. 2 A) and sometimes heavily in-
filtrated by leukocytes (Fig. 2 B). Anti-SPARC staining of
tumor cells in vivo was detectable in both host types (Fig. 2
B), and staining intensity was indistinguishable from that in
primary tumors passed directly in vivo as trocar pieces (not
depicted). Unlike tumors implanted into SPARC
 
 
 
/
 
 
 
 mice,
those in SPARC
 
 
 
/
 
 
 
 mice revealed no SPARC expression
in the stromal compartment or in infiltrating leukocytes
(Fig. 2 B). The Masson’s trichrome staining revealed an
overall reduction of collagen in tumors from SPARC
 
 
 
/
 
 
 
 as
compared with those of the same volume from SPARC
 
 
 
/
 
 
 
mice. The collagen was nearly absent at the growing edge of
the SPARC
 
 /  tumor and was strongly reduced in the in-
tratumor connective septa (Fig. 3, top). Immunostaining
showed that collagen type IV was the predominant stromal
component of lobular tumors from SPARC /  mice,
whereas tumors from SPARC /  mice revealed a general
absence of collagen type IV positive structures, such as the
basement membrane of tumor lobules or vessels either
within or at the tumor edge (Fig. 3, middle). Collagen IV
residual staining was associated with the cytoplasm of some
stromal cells and with the basement membrane of few resi-
Figure 3. N2C tumors in SPARC /  mice show a
defect in collagen deposition. Representative serial sec-
tions of N2C tumors grown s.c. in SPARC /  and
SPARC /  mice and stained with Masson’s trichrome
(top) and immunostained for collagen type IV (middle,
Coll IV) or collagen type I (bottom, Coll I). Masson’s
trichrome revealed decreased collagen in the stroma of
tumors from SPARC /  mice, both at the periphery
(CA, capsular area in SPARC /  mice) and in the
connective tissue septa (arrows). Collagen type IV
staining defined basement membrane structures localizing
at the level of vessels and connective septa (arrows) in
the wild-type mice. Collagen type IV also accounted
for most of the collagen in the capsular area, where
collagen type I staining was less intense. In tumors from
SPARC /  mice, the poor collagen type IV deposition
did not serve to define septa or the peripheral stroma;
only the basement membrane of a preexisting vessel
outside the tumor area showed staining for collagen
type IV (arrowhead).
transferred onto a nylon membrane (Hybond-N; Amersham Bio-
sciences) by Northern blotting. Hybridization was performed
with the 571-bp EcoRI fragment of mouse SPARC cDNA la-
beled with  -[32P]-dCTP using the Multiprime labeling kit (Am-
ersham Biosciences) in the presence of 50% formamide and 10%
dextran sulfate. Filters were washed at high stringency (0.2 
SSC, 0.1% SDS at 55 C for 2 h) and exposed to film for 16–48 h
at  70 C (X-AR5; Kodak).
Online Supplemental Material.  Fig. S1 shows immunostaining
of collagen type I and collagen type IV in tumors from SPARC+/+
mice. Fig. S2 shows collagen deposition (Masson’s trichrome
and immunostaining) in tumors from SPARC+/+   SPARC   
and SPARC      SPARC+/+ chimeras. Fig. S3 shows in vitro
migration of macrophages from SPARC+/+ and SPARC    mice
in response to Mip-1 . Fig. S4 shows leukocyte infiltration in the
ears of SPARC+/+ and SPARC    mice after phorbol ester–
induced inflammation. Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20030202/DC1.
Results
Impaired Tumor Stroma and Defective Collagen Type IV
Deposition in the Absence of Host-produced SPARC. Thoracic-
and inguinal-transformed mammary glands were collected
from Her2neu transgenic BALB-neuT mice. Half of each
primary tumor nodule was used to establish cell lines,
whereas the other half was used for in vivo passages as tro-
car pieces. Carcinoma cell lines N2C, N1G, and N3D
were characterized for SPARC expression by Northern
blot analysis and immunostaining.T
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dent vessels (Fig. 3, middle). A structural vessel outside the
tumor area, and likely not undergoing remodeling, stains
strongly for collagen type IV (Fig. 3, arrowheads). Collagen
type I was almost exclusively localized at the periphery of
tumors from SPARC /  mice and its immunostaining was
less intense in tumors from SPARC /  mice (Fig. 3, bot-
tom). The distinct specificity of Abs to collagens types I
and IV was confirmed by double immunostaining (Fig.
S1, available at http://www.jem.org/cgi/content/full/jem.
20030202/DC1).
To test whether the lack of SPARC by tumor-associated
host leukocytes accounted for impaired stroma formation,
SPARC /  mice were lethally irradiated and transplanted
with BM from CB6F1 (SPARC / ) mice before injection
with N2C carcinoma cells. In the presence of SPARC-
producing donor leukocytes, stroma appeared identical to
that of N2C tumors grown in SPARC /  mice; however,
tumors from reciprocal chimeras in which BM of
SPARC /  donors transplanted into SPARC /  (CB6F1)
recipients showed the same reduced stroma and impaired
collagen deposition seen in SPARC /  mice (Fig. 4 and
Fig. S2, A and B available at http://www.jem.org/cgi/
content/full/jem.20030202/DC1). In particular, serial
sections of N2C tumor s.c. grown in SPARC /    
SPARC /  chimeras revealed donor (H-2Kb) SPARC-
producing macrophages (F4/80 ), accounting for the ma-
jor cellular component of the stroma and colocalizing with
a bright staining of collagen type IV (Fig. 4 A). In recipro-
cal SPARC /    SPARC /  chimeras in which BM of
SPARC /  donors was transplanted into SPARC / 
(CB6F1) recipients, donor take was judged based on loss of
H-2Kb expression in PBMCs; thus, tumor sections could
only be stained with H-2Kd (common to host and donor).
Because the tumors expressed low levels of H-2Kd, which
were undetectable by immunohistochemistry, only stromal
cells were decorated by the H-2Kd mAb. Most of those
stromal cells also stain for F4/80 in areas of weak, residual
collagen type IV staining, confirming that in tumors from
SPARC /     SPARC /  chimeras, macrophages re-
cruited from donor BM are unable to produce SPARC and
are associated with reduced collagen type IV (Fig. 4 B).
Correlation between Tumorigenicity and Leukocyte Infiltra-
tion. Because stroma formation appeared to depend on
SPARC produced by leukocytes, we analyzed the extent of
leukocyte infiltration and its possible influence on the
outgrowth of transplanted tumors in SPARC /  and
SPARC /  mice. The total leukocyte population that was
immunostained using mAb to CD45 was significantly
larger in tumors from both SPARC /  mice and mice re-
ceiving BM from SPARC /  donors than in tumors from
SPARC /  and SPARC /    SPARC /  chimeras (Fig.
5, A and B). Although leukocytes in tumors from
SPARC /  mice localized in the perilobular stroma, those
in tumors from SPARC /  mice were more dispersed,
with some deeply infiltrating the tumor parenchyma (Fig. 5
B), but mostly associated to necrotic areas (Fig. 6) or with
some areas of less defined perilobular septa.
Figure 4. Stroma deposition in tumors from chimeric mice.
SPARC /  (CB6F1, H-2bd)   SPARC /  (BALB/c, H-2d) chimeric
mice (A) and reciprocal chimeras SPARC /  (BALB/c, H-2d)   
SPARC /  (CB6F1, H-2b-d) mice (B) were injected s.c. with N2C
tumor cells 8 wk after BMT. BMT design for each type of chimera and
expression of donor MHC class I antigens in PBMCs of transplanted
mice before and after BMT are shown above each panel. Cryostat sec-
tions of tumors were stained for MHC-I donor antigen, macrophages
(F4/80), SPARC, and collagen type IV. In SPARC /    SPARC / 
chimeras, donor (H-2Kb) SPARC-producing macrophages (F4/80 )
represent the major cellular component of the stroma (S) and colocalize
with a bright staining of collagen type IV. However, in tumors from
SPARC /    SPARC /  chimeras, macrophages recruited from donor
BM are unable to produce SPARC and are associated with reduced
collagen type IV. In these tumors, necrotic (n) areas are as frequent as in
tumors from SPARC /  mice.T
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Analysis of N2C tumor growth kinetics revealed sig-
nificantly reduced outgrowth in SPARC /  and SPARC /   
SPARC /  chimeric mice (i.e., the lines with the highest
number of infiltrating leukocytes, as compared with tumors
from SPARC / , SPARC /    SPARC /  [Fig. 5 C]
and control chimeric mice [not depicted]). Thus, in the ab-
sence of SPARC, leukocytes might infiltrate the tumor
more easily and may counter tumor growth.
Characterization of Infiltrating Leukocytes. Immunostain-
ing with Abs to various leukocyte subpopulations indicated
that all leukocyte types were more abundant in tumors
from SPARC /  than SPARC /  mice (Table I). CD11b 
staining, which detects both macrophages and granulo-
cytes, is abundant around the large area of necrosis that
characterizes tumors from SPARC /  mice (Fig. 6 and not
depicted).
In situ hybridization revealed expression of TNF  and,
to a lesser extent, IFN  mRNA in infiltrating cells around
and within necrotic areas of the SPARC /  mouse tumors
Figure 5. Tumorigenicity of N2C cells is inversely correlated with the
number of infiltrating leukocytes. Cryostat sections of tumor from
SPARC / , SPARC / , SPARC /    SPARC / , and SPARC /   
SPARC /  chimeric mice were immunostained for the common leuko-
cyte antigen CD45. Quantitative analysis of CD45  cells (A) revealed sig-
nificantly (Student’s t test) higher number of CD45  cells in tumors from
SPARC /  and SPARC /    SPARC /  chimeric mice ( /     / )
as compared with tumors from SPARC /  mice and SPARC /    
SPARC /  chimeras ( /     / ). (B) Localization of CD45  cells
within the tumors. In wild-type and chimeric SPARC /    SPARC / 
mice, CD45  cells were localized mainly in the connective septa completely
defining lobular structures, with only a few cells infiltrating the tumor
parenchyma. In tumors from SPARC /  mice and SPARC /    
SPARC /  chimeras, CD45  cells were distributed in the residual septa,
which were sometimes completely infiltrated by these cells (arrowheads)
but also localized within the tumor parenchyma. Analysis of N2C tumor
growth kinetics (C) showed that growth was impaired in SPARC /  and
SPARC /     SPARC /  chimeras as compared with wild-type and
SPARC /    SPARC /  mice (*, P   0.005; Student’s t test at day 27).
Original magnification, 100.
Figure 6. Expression of TNF 
and IFN  in tumors N2C from
SPARC /  mice. In situ hybridiza-
tion analysis revealed expression of
TNF  mRNA both in stromal cells
(arrows) and cells localized within a
necrotic area (arrowheads), whereas
IFN  was detected only in cells
within the necrotic area. Cells local-
izing in the necrotic area stained
with mAb to CD11b, which defines
granulocytes and macrophages.
Figure 7. Enhanced tumor
growth in SPARC /  mice
treated with neutralizing anti-
bodies against TNF  and IFN .
Mean    SD final volume of
N2C tumors was compared
22 d after s.c. injection into
SPARC /  and SPARC / 
mice treated i.p. with 200  g of
mAb against both TNF  and
IFN  starting 1 d after tumor
cell injection. Results are from
one experiment of three per-
formed. P-value was determined
by Student’s t test.T
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(Fig. 6). TNF  was also expressed in cells localized in the
thin stroma delimiting the less organized lobular structures.
To test the potential role of these cytokines in the reduced
growth of N2C tumors in SPARC /  as compared with
SPARC /  mice, tumor outgrowth was monitored in
mice treated twice per week with neutralizing mAb against
TNF  and IFN  starting 1 d after the N2C cell injection.
Tumor growth was significantly (P   0.001) accelerated
in SPARC /  mice with respect to control untreated
SPARC /  mice, whereas tumor growth was similar in
treated versus untreated SPARC /  mice (Fig. 7). Indeed,
in antibody-treated SPARC /  mice, N2C tumor growth
was similar to that observed in SPARC /  mice.
Impaired Vascular Supply in N2C Tumors from SPARC / 
Mice. Reduced mammary tumor growth might reflect re-
duced nutrient and/or cytokine supply related to impaired
peritumoral stroma (34). Analysis of vascularization based on
PECAM-1 (CD31) immunostaining in the peritumoral and
perilobular stroma from SPARC /  and SPARC /  mice
revealed small and few vessels supplying tumors from
SPARC /  mice, as compared with the highly vascularized
tumors from SPARC /  mice (Fig. 8). Calculation of the
vascularized (CD31 ) area relative to that of tumors in
SPARC /  and SPARC /  mice (five mice in each group;
10 observations per mouse in defined tumor area) indicated
a significantly (P   0.005) smaller vascularized area in tu-
mors from SPARC /  mice (4.7   1.9% vs. 11.9   5.5%).
Discussion
SPARC has been implicated in tumor–host interactions
by virtue of its ability to bind several matrix components,
such as thrombospondin-1, vitronectin, fibrillar collagen,
and collagen type IV. This notion is strengthened by the
observation that SPARC expression is associated with tis-
sues undergoing repair, remodeling, and turnover (for re-
view see reference 14). However, the precise role of
SPARC in tumorigenesis and tumor progression has re-
mained unclear because of disparate results in numerous
papers. In ovarian carcinomas, SPARC down-regulation
has been associated with tumor progression because it is
expressed in normal ovary cells and gradually lost as disease
progresses (35, 36). Moreover, restoration of SPARC ex-
pression in ovarian carcinoma cells by gene transduction
suppresses tumorigenesis by inducing apoptosis (37). Simi-
lar growth suppression has been reported for human breast
cancer cells induced to express SPARC by treatment with
doxicyclin (38). By contrast, SPARC has protumoral ac-
tivity in other tumor cell types. For example, SPARC in-
hibition by antisense oligonucleotides reduced tumorige-
nicity of melanoma cell lines in nude mice, and melanoma
cell clones with the lowest expression of SPARC lost the
ability to adhere (25), an ability required for eventual inva-
sion. Moreover, glioma cell lines transfected to express
different amounts of SPARC acquire an increasingly ma-
lignant phenotype as a function of increased SPARC ex-
pression (39–41).
Although tissue variation might explain the conflicting
results, an added complexity stems from the fact that both
tumor and stroma cells can produce SPARC. In the present
work, we developed a mouse model that allowed dissection
of the role of SPARC produced by BM-derived inflamma-
tory cells from that of SPARC-producing tumor cells.
Table I. Profile of Leukocytes Infiltrating Tumors from SPARC /  and SPARC /  Mice
F4/80 CD11b Ly-6G CD11c CD4 CD8
SPARC  /  176.9   74.5a 147.0   136.1 32.7   11.2 68.8   43.4 43.7   45.0 1.4   2
SPARC /  564.5   287.8 545   129 130.4   70.0 328.0   128.0 146.0   95.9 14.0   5.6
Data are from five mice for both SPARC /  and SPARC /  mice. For each sample, 10 randomly chosen fields were analyzed, and the data were
compared using Student’s t test. P   0.005 for all groups.
aMean number of cells/mm2 ( SD) positive for immunostaining.
Figure 8. Immunohistochemical characterization of blood vessels associ-
ated with N2C tumors from SPARC /  and SPARC /  mice. N2C tumor
obtained from SPARC /  and SPARC /  mice were immunostained with
mAbs against CD31/PECAM-1 to characterize tumor-associated blood
vessels. Although tumors from SPARC /  mice were highly vascular-
ized, those from SPARC /  mice showed a dramatic reduction in
number and size of tumor-associated blood vessels both at the periphery
(top; original magnification, 100) and inside the tumor (bottom; original
magnification, 200).T
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When injected into SPARC /  mice, the BALB-neuT–
derived N2C, N1G, and N3D mammary carcinoma cell
lines grew as a solid tumor characterized by a well-struc-
tured stroma comprised predominantly of macrophages and
of collagen type IV defining the lobular structure of these
tumors. The same tumors grown in congenic SPARC / 
mice showed a clear defect in matrix assembly that was not
due to impaired recruitment of stroma cell components but
rather to a defect in deposition of collagen type IV. Altered
collagen type IV deposition has been detected in the spe-
cialized ECM that forms the lens capsule (28) in SPARC / 
mice. Our results indicate that alteration of collagen type
IV assembly is a more general defect associated with a
SPARC deficit.
To better illustrate the distinct role of host-versus-
tumor–produced SPARC, most of our experiments were
performed using the N2C cell line, the highest SPARC
producer, and using BM chimeras, in which SPARC pro-
duction derives from cells of BM origin. Our analysis of tu-
mor matrix assembly in SPARC /    SPARC / , recip-
rocal SPARC /     SPARC / , and control chimeric
mice injected with N2C cells 8 wk after BMT revealed de-
fective collagen, mainly type IV, only in mice receiving
BM from SPARC /  donors. This finding demonstrates
the crucial role of SPARC produced by BM-derived cells
in collagen type IV assembly in the tumor environment,
and the inability of tumor-produced SPARC to substitute
that from leukocytes in organizing the intervening stroma
defining lobular structures of this mammary carcinoma.
Our results add a matricellular protein to the list of factors
that, when produced by inflammatory cells, can promote
malignant outgrowth rather than normal development (for
review see references 1, 2).
We investigated whether impaired matrix formation in
tumors from SPARC /  mice has any functional signifi-
cance for leukocyte migration. Migration of T lymphocytes
through basement membrane has been shown to require
MMP-9 secretion (42), and T cell homing to extravascular
sites requires penetration of the subendothelial lamina, a
specialized connective tissue formed by collagen types IV
and V (43). Migration of Langerhans cells from the skin to
draining lymph nodes also requires MMPs to cleave col-
lagen fibers that hamper cell migration (44). The same has
been described for macrophages invading tissues (10).
Thus, a less organized stroma is expected to favor cell mi-
gration and, therefore, leukocyte infiltration. The paren-
chyma of tumors from SPARC /  and SPARC /    
SPARC /  chimeric mice were infiltrated by a large
number of CD45  leukocytes further identified as macro-
phages (CD11b  and F4/80 ), granulocytes (CD11b  and
Ly6G ), and less numerous lymphocytes (CD4 ) and den-
dritic cells (CD11c ). N2C tumors from SPARC /   
SPARC /  chimeras were infiltrated with macrophages
only bordering tumor lobes as part of the structural stroma.
Such different patterns of leukocyte infiltration are not due
to a differential intrinsic migratory capacity of cells from
SPARC /  and SPARC /  mice, because macrophages
(Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20030202/DC1) and dendritic cells (not depicted)
from the two mouse strains migrate equally well in vitro in
response to MIP-1  and MIP-3 , respectively. The more
extensive CD45  cell infiltration of inflamed tissue, such as
mouse ear skin treated with TPA in SPARC /  than in
SPARC /  mice (Fig. S4, available at http://www.jem.
org/cgi/content/full/jem.20030202/DC1), is consistent with
a role of SPARC in leukocytes migration in vivo.
TGF  is reportedly down-regulated in absence of
SPARC (45), and Hazelbag et al. (46) found a direct corre-
lation between increased TGF  expression, increased col-
lagen type IV production, and reduced leukocyte infiltra-
tion in cervical cancer, a result that mirrors our findings in
which the absence of SPARC correlated with low collagen
type IV and increased leukocyte infiltration.
Solid tumors require stroma for growth beyond a mini-
mal size (47), and we found that poor stroma organization
was associated with reduced tumor growth. One possible
explanation for this growth reduction is immunologically
based, a context in which the role of SPARC has never
been investigated previously. Stroma may act as a shield to
protect tumors from immune cell infiltration (48) and may
participate in processes leading to tumor antigen presenta-
tion (49). In the heavily infiltrated N2C tumors from
SPARC /  mice, most of the granulocytes and macro-
phages were localized within the numerous and large ne-
crotic areas and expressed TNF  and IFN ; inhibition of
these cytokines by neutralizing mAb abrogated the delayed
growth of tumors in SPARC /  mice. These cytokines
can kill tumor cells both directly and indirectly through ac-
tivation of PMNs that interact with tumor cells and endo-
thelial cells for subsequent lysis (50).
A second possibility to explain the impaired tumor
growth in SPARC /  mice is a reduced blood supply be-
cause stroma is the area of vessels cooptation (51). Our
analysis revealed fewer and smaller blood vessels in tumors
from SPARC /  than SPARC /  mice, consistent with
earlier suggestions (52) and with previous in vitro analyses
that correlated SPARC expression with tumor neoangio-
genesis (53, 54). Moreover, a reduced number of blood
vessels was found in vivo in the capsule surrounding biom-
aterials implanted in SPARC /  mice as part of the host
reaction to foreign body (55).
Together, our data demonstrate a role for host leukocyte–
produced SPARC in determining the structure and function
of tumor-associated stroma through the organization of col-
lagen, which in lobular mammary carcinoma, is mainly type
IV. Whether facilitated leukocyte infiltration favors tumor-
specific immune attack remains to be investigated.
Recently, Brekken et al. (56) reported that the SPARC
producer 3LL lung carcinoma cell line and the nonpro-
ducer EL-4 lymphoma line grew faster in SPARC /  mice
backcrossed for four generations to B6 than in wild-type
B6 mice. This finding is apparently contradictory only be-
cause 3LL tumors also had reduced collagen, albeit it was
collagen type I whereas type IV was the most affected in
our model because of the different histotype. Differences in
the prominent type of collagen and its proteolysis can gen-T
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erate fragments favoring or inhibiting tumor angiogenesis.
Indeed, trimer carboxyl propeptide of collagen type I is
chemotactic for endothelial cells (57), whereas collagen
type IV degradation by MMP-9 generates tumstatin that
induces apoptosis of proliferating endothelial cells (58). The
tumor growth differences might also rest in possibility that
cell lines established over 30 yr of passages (59) are likely
less sensitive to environmental factors than primary cell
lines. Indeed, N2C carcinomas do not grow when trans-
planted outside the mammary fat pad (unpublished data),
whereas 3LL tumors grow ectopically and even overcome
MHC barriers (60).
If diverse histotypes actually underlie differential tumor
growth in SPARC / , further analysis of tumor-derived
SPARC seems warranted because it is not clear whether it
differs functionally from that of host origin. Our recently
obtained mammary cell lines from SPARC /  mice carry-
ing the mouse mammary tumor virus–HER-2/neu–acti-
vated rat oncogene should help to determine the role of tu-
mor-derived SPARC, whereas BMT from SPARC / 
into SPARC /  neu /  mice should indicate the role of
BM-derived SPARC in the various phases of mammary
gland transformation.
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